S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Oxygen Biotherapeutics Issued U.S. Patent for Dermatologic Indications (2013/9/10)|
|Oxygen Biotherapeutics Signs Agreement to Acquire Phase 3, FDA Fast Track Product to Pursue Potential $600 Million Cardiovascular Market ()|
|Oxygen Biotherapeutics Closes the Acquisition of Phyxius Pharma Assets Related to Levosimendan; John Kelley Appointed CEO of Oxygen Biotherapeutics (2013/11/14)|
|Oxygen Biotherapeutics Provides a Business Review and Update in Conjunction with Filing of Second Quarter Fiscal Year 2014 Financials (2013/12/19)|
|Oxygen Biotherapeutics Announces Key Details of Phase 3 Trial Protocol for levosimendan ()|
|Oxygen Biotherapeutics Inc., Announces the Appointment of Industry Veteran Gerald Proehl to its Board of Directors (2014/4/4)|
|Oxygen Biotherapeutics Submits to FDA Results of Requested Nonclinical Studies ()|
|Oxygen Biotherapeutics Selects Duke Clinical Research Institute to Conduct Phase 3 Trial of Levosimendan ()|
|Oxygen Biotherapeutics Strengthens Balance Sheet Through $4.6 Million Debt Conversion ()|
|Oxygen Biotherapeutics Receives $6 Million in Net Proceeds from Warrant Exercises ()|
Click above to view more mutual fund data and stats for oxbt - Oxygen Biotherapeutics, Inc..